SECURITY AND EXCHANGE COMMISSION
Washington, DC 20549
REPORT IN PROGRESS
IN ACCORDANCE WITH ARTICLE 13 OR 15 (d) OF THE
SECURITIES EXCHANGES ACT OF 1934
Report date (Date of first reported event): December 31, 2021
ADAMIS PHARMACEUTICAL COMPANY
(Exact name of the holder as specified in the charter)
(State or other jurisdiction
|(Commission file number)||
11682 El Camino Real, Suite 300
San Diego, California
|(Address of the main executive offices)||(Postal code)|
Cardholder’s phone number, including area code: (858)997-2400
(Old name or old address, if changed since the last report.)
Check the appropriate box below if the filing of Form 8-K is intended to simultaneously satisfy the filer’s filing obligation under any of the following provisions (see General Instruction A.2. Below ):
|??||Written communications in accordance with Rule 425 of the Securities Act (17 CFR 230.425)|
|??||Solicitation of documents in accordance with Rule 14a-12 of the Exchange Act (17 CFR 240.14a-12)|
|??||Pre-launch communications in accordance with Rule 14d-2 (b) of the Exchange Act (17 CFR 240.14d-2 (b))|
|??||Pre-launch communications pursuant to Exchange Act Rule 13e-4 (c) (17 CFR 240.13e-4 (c))|
Securities registered in accordance with Section 12 (b) of the Exchange Act:
|Title of each class||Trading symbol (s)||
Name of each exchange on
|Ordinary actions||ADMP||NASDAQCapital market|
Indicate with a check mark whether the declarant is an emerging growth company within the meaning of rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or of rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
|Emerging, growing company ??|
If this is an emerging growth company, indicate with a check mark whether the declarant has chosen not to use the extended transition period to comply with the new financial or revised accounting standards provided for under Article 13 (a) of the Exchange Act. ??
Item 3.01 Notice of De-listing or Non-Compliance with a Continuing Listing Rule or Standard; Registration transfer.
On December 31, 2021, Adamis Pharmaceuticals Corporation (the “Company”) received a notice from the Nasdaq Stock Market Listing Qualifications Department (“Nasdaq”) advising the Company that for 30 consecutive business days, the closing bid price of The common share was less than $ 1.00 per share, which is the minimum closing bid price required to maintain the Nasdaq capital market listing under the 5550 (a) Market Rule (2 ). This notice has no immediate effect on the Nasdaq listing of the Company or the trading of its common shares.
In accordance with Nasdaq Marketplace Rule 5810 (c) (3) (A), the Company has 180 calendar days from the date of notification, or until June 29, 2022, to restore compliance. If, at any time before June 29, 2022, the bid price of the Company’s common shares closes at or above $ 1.00 per share for at least 10 consecutive business days, Nasdaq will provide written notification that the Company has complied with the minimum bid price. requirement, and the matter would be resolved. The notification letter also stated that if the Company does not restore compliance within the initial compliance period, it may be eligible for an additional 180-day compliance period. To benefit from additional time, the Company would be required to meet the continuous listing requirement for the market value of publicly held shares and all other initial listing standards for the Nasdaq Capital Market, at the ‘exception to the bid price requirement, and should provide written notice of a plan to remedy the deficiency during the second compliance period. If the Company meets these requirements, Nasdaq will notify the Company that it has been granted an additional 180 calendar days to restore compliance. However, if it appears to Nasdaq staff that the Company will not be able to remedy the impairment, or if the Company is not eligible for some other reason, staff will advise the Company that they will not be able to do so. granted 180 additional days to comply and be expunged at that time. In the event of such notification, the Company may appeal against staff’s decision to delist its securities, but there can be no assurance that such an appeal would be successful. The Company intends to monitor the closing bid price of its common shares and will review available strategies with the objective of meeting the minimum bid price requirement. However, there can be no assurance that the Company will be able to re-comply with the minimum bid price requirements or that it will otherwise comply with the other Nasdaq listing rules.
In accordance with the requirements of the Securities Exchange Act of 1934, the Holder has duly caused this report to be signed on his behalf by the undersigned, duly authorized.
|ADAMIS PHARMACEUTICAL COMPANY|
|Dated: January 4, 2022||Through:||/ s / David C. Benedicto|
|Last name:||David C. Benedicto|